This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd3747/MediaObjects/41573_2012_Article_BFnrd3747_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd3747/MediaObjects/41573_2012_Article_BFnrd3747_Fig2_HTML.jpg)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Box S1
Background information and data sources (PDF 131 kb)
Rights and permissions
About this article
Cite this article
Smith, J., Townsend, S., Singh, N. et al. FDA advisory committee meeting outcomes. Nat Rev Drug Discov 11, 513–514 (2012). https://doi.org/10.1038/nrd3747
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3747
This article is cited by
-
Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC)
Therapeutic Innovation & Regulatory Science (2021)